2025
Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors
Galloway T, Pugh S, Ridge J, Nguyen-Tan P, Rosenthal D, Gillison M, Garden A, Dunlap N, Caudell J, Jones C, Bauman J, Bahig H, Shenouda G, Currey A, Koyfman S, Stokes W, Read N, Lyness J, Yom S, Le Q. Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40473230, DOI: 10.1016/j.ijrobp.2025.05.064.Peer-Reviewed Original ResearchIntensity modulated radiation therapyOropharynx cancer patientsOropharynx cancerFeeding tube useTube useAccelerated fractionationTreatment initiationPredictive factorsFeeding tubeIntensity modulated radiation therapy techniquesTreated with 3DCRTSecondary analysis of patientsT4 tumor stageAnalysis of patientsTreatment related factorsPost hoc secondary analysisTreatment completionYears of smokingSecondary analysisChemoradiation trialsConcurrent chemotherapyMedian followupConcomitant boostConformal radiationRadiation therapyEnzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer
Azad A, Petrylak D, Iguchi T, Shore N, Villers A, Gomez-Veiga F, Alcaraz A, Alekseev B, Szmulewitz R, Holzbeierlein J, Rosbrook B, Ma J, Zohren F, El-Chaar N, Haas G, Stenzl A, Armstrong A. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer. JAMA Network Open 2025, 8: e258751. PMID: 40332939, PMCID: PMC12059972, DOI: 10.1001/jamanetworkopen.2025.8751.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerProstate-specific antigen levelRadiographic progression-free survivalUndetectable prostate-specific antigenAndrogen deprivation therapyProstate-specific antigenProstate-specific antigen declineClinical outcomesOverall survivalProstate cancerClinical trialsHazard ratioPatients treated with enzalutamideHormone-sensitive prostate cancerPhase 3 randomized clinical trialAssociated with improved survivalStudy enrollmentProgression-free survivalMetastatic prostate cancerRadiographic disease progressionClinical end pointsPost hoc secondary analysisRandomized clinical trialsReduced riskSecondary analysis
2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Gebrael G, Jo Y, Swami U, Plets M, Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2419966. PMID: 38980676, PMCID: PMC11234233, DOI: 10.1001/jamanetworkopen.2024.19966.Peer-Reviewed Original ResearchConceptsProgression-free survivalAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerBone painOverall survivalPost hoc secondary analysisProstate cancerSurvival outcomesPain statusAssociated with shorter progression-free survivalClinical trialsPresence of bone painProstate-specific antigen levelAssociated with worse overall survivalCastration-resistant prostate cancerShorter progression-free survivalIntention-to-treat populationSecondary analysisZubrod performance statusHigh-volume diseaseCompare survival outcomesCox proportional hazards regression modelsSecondary end pointsProportional hazards regression models
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply